{"name":"ITM Oncologics GmbH","slug":"itm-oncologics-gmbh","ticker":"","exchange":"","domain":"itmoncologicsgmbh.com","description":"ITM Oncologics GmbH is a biotechnology company focused on the development of innovative radiopharmaceuticals for the treatment of cancer. The company's pipeline includes two investigational drugs in Phase 1 clinical trials, [177Lu]Lu-DPI-4452 and [68Ga]Ga-DPI-4452, which are designed to target specific tumor types with precision.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"[68Ga]Ga-DPI-4452","genericName":"[68Ga]Ga-DPI-4452","slug":"68ga-ga-dpi-4452","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"[68Ga]Ga-DPI-4452","genericName":"[68Ga]Ga-DPI-4452","slug":"68ga-ga-dpi-4452","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}